EPISODE · Aug 8, 2012 · 18 MIN
Emerging LDL Therapies
from Lipid Luminations
Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Peter Toth, MD Host Dr. Alan Brown is joined by Peter P. Toth, MD, PhD, director of preventive cardiology in Sterling Rock Falls Clinic and clinical professor at the University of Illinois School of Medicine in Peoria, Illinois. Dr. Toth is the current president of the National Lipid Association. One of the most intensively studied drugs are statins. However, will statins continue to be the miracle drugs that health care professionals and patients rely on? What are statins current role in therapy for dyslipidemia patients? In this discussion, Dr. Toth will address these questions. He will also review the new therapies for lowering LDL and whether LDL should continue to be the target for risk assessment and treatment. Brought to you by:
What this episode covers
Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Peter Toth, MD Host Dr. Alan Brown is joined by Peter P. Toth, MD, PhD, director of preventive cardiology in Sterling Rock Falls Clinic and clinical professor at the University of Illinois School of Medicine in Peoria, Illinois. Dr. Toth is the current president of the National Lipid Association. One of the most intensively studied drugs are statins. However, will statins continue to be the miracle drugs that health care professionals and patients rely on? What are statins current role in therapy for dyslipidemia patients? In this discussion, Dr. Toth will address these questions. He will also review the new therapies for lowering LDL and whether LDL should continue to be the target for risk assessment and treatment. Brought to you by:
NOW PLAYING
Emerging LDL Therapies
No transcript for this episode yet
Similar Episodes
Jun 1, 2026 ·21m
Apr 29, 2026 ·11m
Apr 16, 2026 ·27m